Justin C Brown1, Michael O Harhay2, Meera N Harhay3. 1. Division of Population Science, Dana-Farber Cancer Institute, Boston, MA, USA. Electronic address: justinc_brown@dfci.harvard.edu. 2. Pallaitive and Advanced Illness Research Center, University of Pennsylvania School of Medicine, Philadelphia, PA, USA. 3. Division of Nephrology, Department of Medicine, Drexel University College of Medicine, Philadelphia, PA, USA.
Abstract
OBJECTIVE: To quantify the prevalence of self-reported major mobility disability (SR-MMD) and its association with mortality in a nationally-representative sample of cancer survivors. MATERIALS AND METHODS: This study included patients with a history of cancer who participated in the National Health and Nutrition Examination Survey 19992010. SR-MMD was defined as self-reported difficulty or inability to walk a quarter of a mile. Vital status through December 15, 2011 was ascertained from the United States National Center for Health Statistics. Multivariable-adjusted Cox regression models were used to quantify the hazard ratio (HR) and 95% confidence interval (CI) between SR-MMD and mortality. RESULTS: The study included 1458 cancer survivors who averaged 67.1 years of age. At baseline, 201 (13.7%) participants had SR-MMD. During a median follow-up of 4.7 years, 434 (29.8%) participants died. SR-MMD was independently associated with a higher risk of all-cause mortality [HR: 2.15 (95% CI: 1.56-2.97); P < 0.001] and cancer-specific mortality [HR: 2.49 (95% CI: 1.53-4.07); P < 0.001]. The association between SR-MMD and all-cause mortality was not modified by age, sex, time since cancer diagnosis, body mass index, or comorbid health conditions. CONCLUSION: SR-MMD is an easily ascertainable metric of physical function that is associated with a higher risk of mortality among cancer survivors. Integrating measures of physical function may help to guide clinical decision-making and improve long-term prognostication in this population. Interventions that prevent the development of SR-MDD, such as physical activity, should be evaluated in this population.
OBJECTIVE: To quantify the prevalence of self-reported major mobility disability (SR-MMD) and its association with mortality in a nationally-representative sample of cancer survivors. MATERIALS AND METHODS: This study included patients with a history of cancer who participated in the National Health and Nutrition Examination Survey 19992010. SR-MMD was defined as self-reported difficulty or inability to walk a quarter of a mile. Vital status through December 15, 2011 was ascertained from the United States National Center for Health Statistics. Multivariable-adjusted Cox regression models were used to quantify the hazard ratio (HR) and 95% confidence interval (CI) between SR-MMD and mortality. RESULTS: The study included 1458 cancer survivors who averaged 67.1 years of age. At baseline, 201 (13.7%) participants had SR-MMD. During a median follow-up of 4.7 years, 434 (29.8%) participants died. SR-MMD was independently associated with a higher risk of all-cause mortality [HR: 2.15 (95% CI: 1.56-2.97); P < 0.001] and cancer-specific mortality [HR: 2.49 (95% CI: 1.53-4.07); P < 0.001]. The association between SR-MMD and all-cause mortality was not modified by age, sex, time since cancer diagnosis, body mass index, or comorbid health conditions. CONCLUSION:SR-MMD is an easily ascertainable metric of physical function that is associated with a higher risk of mortality among cancer survivors. Integrating measures of physical function may help to guide clinical decision-making and improve long-term prognostication in this population. Interventions that prevent the development of SR-MDD, such as physical activity, should be evaluated in this population.
Authors: Arti Hurria; Kayo Togawa; Supriya G Mohile; Cynthia Owusu; Heidi D Klepin; Cary P Gross; Stuart M Lichtman; Ajeet Gajra; Smita Bhatia; Vani Katheria; Shira Klapper; Kurt Hansen; Rupal Ramani; Mark Lachs; F Lennie Wong; William P Tew Journal: J Clin Oncol Date: 2011-08-01 Impact factor: 44.544
Authors: Martine T E Puts; Johanne Monette; Veronique Girre; Carmela Pepe; Michele Monette; Sarit Assouline; Lawrence Panasci; Mark Basik; Wilson H Miller; Gerald Batist; Christina Wolfson; Howard Bergman Journal: Crit Rev Oncol Hematol Date: 2010-05-04 Impact factor: 6.312
Authors: E M Simonsick; A B Newman; M C Nevitt; S B Kritchevsky; L Ferrucci; J M Guralnik; T Harris Journal: J Gerontol A Biol Sci Med Sci Date: 2001-10 Impact factor: 6.053
Authors: Milan Chang; Jiska Cohen-Mansfield; Luigi Ferrucci; Suzanne Leveille; Stefano Volpato; Nathalie de Rekeneire; Jack M Guralnik Journal: J Am Geriatr Soc Date: 2004-12 Impact factor: 5.562
Authors: Matthew T Seymour; Lindsay C Thompson; Harpreet S Wasan; Gary Middleton; Alison E Brewster; Stephen F Shepherd; M Sinead O'Mahony; Timothy S Maughan; Mahesh Parmar; Ruth E Langley Journal: Lancet Date: 2011-05-11 Impact factor: 79.321
Authors: Elizabeth A Salerno; Pedro F Saint-Maurice; Erik A Willis; Steven C Moore; Loretta DiPietro; Charles E Matthews Journal: Cancer Epidemiol Biomarkers Prev Date: 2021-03-04 Impact factor: 4.090
Authors: Xinxia Zhu; Kevin G Burfeind; Katherine A Michaelis; Theodore P Braun; Brennan Olson; Katherine R Pelz; Terry K Morgan; Daniel L Marks Journal: J Cachexia Sarcopenia Muscle Date: 2019-01-21 Impact factor: 12.910